Chief Physician, Associate Professor, and Master's Supervisor in the Department of Gastrointestinal Medical Oncology at Beijing Cancer Hospital. Graduated from Peking University School of Clinical Oncology in 2009 with a Doctorate in Oncology, and has been engaged in clinical oncology work for nearly 20 years. Specializes in individualized and multidisciplinary comprehensive treatment of digestive system tumors, including neuroendocrine neoplasms, gastric cancer, esophageal cancer, colorectal cancer, and pancreatic cancer, with extensive clinical experience. Well-versed in the latest international advancements across various fields, with research primarily focused on molecular subtyping, individualized multidisciplinary treatment, and conversion therapy for neuroendocrine neoplasms. Has participated in the enrollment and management of dozens of domestic and international clinical studies. Published over ten related papers as first/corresponding author in journals such as Clinical Cancer Research, Cancer, Cancer Communications, Cancer Science, Oncotarget, and Medicine. Led two national and provincial/ministerial-level research projects. Received the First Prize of Science and Technology from the Chinese Anti-Cancer Association and the First Clinical Medical Award from Peking University. Social Affiliations: Member of the Neuroendocrine Neoplasms Committee of the Chinese Society of Clinical Oncology (CSCO); Member of the Neuroendocrine Neoplasms Branch of the China International Exchange and Promotive Association for Medical and Health Care; Editorial Director of the Editorial Department of the Chinese Journal of Medical Frontiers (Electronic Edition). Representative Papers, Monographs, and Patents 1. Ming Lu, Panpan Zhang (joint first author), Lin Shen, et al, Efficacy, safety and biomarkers of toripalimab in patients with recurrent or metastatic neuroendocrine neoplasms: a multiple-center phase Ib trial. (Clinical Cancer Research. IF 10.199); 2. Panpan Zhang, Jie Li, Lin Shen, Ming Lu, et al. Etoposide and cisplatin versus irinotecan and cisplatin as the first-line therapy for advanced poorly differentiated gastroenteropancreatic neuroendocrine carcinoma: a randomized phase II study. (Cancer. IF 6.102) 3. Yansuo Cao, Yutong Ma, Jiangyuan Yu……Ming Lu. Favorable response to immunotherapy in a pancreatic neuroendocrine tumor with temozolomide-induced high tumor mutational burden. Cancer Communications. 2020;1–6. 4. Li Jie Lu M, ZH Lu et al. Irinotecan plus cisplatin followed by octreotide long-acting release maintenance treatment in advanced gastroenteropancreatic neuroendocrine carcinoma：IPO-NEC Study. Oncotarget.2016. 5. Panpan Zhang Jiangyuan Yu,Jie Li, Lin Shen , Nan Li, Hua Zhu, Shizhen Zhai,Yan Zhang, Zhi Yang, and Ming Lu. Clinical and Prognostic Value of PET/CT Imaging with Combination of 68Ga-DOTATATE and 18F-FDG in Gastroenteropancreatic Neuroendocrine Neoplasms. Contrast Media & Molecular Imaging. 2018 Feb 26;2018:2340389. 6. Lu M, Wang X, Shen L et al. Nimotuzumab Plus Paclitaxel and Cisplatin as the 1st Line Treatment for Advanced Esophageal Squamous Cell Cancer (ESCC): a Single Centre Prospective Phase II Trial. Cancer Sci. 2016 Apr;107(4):486-90. 7. Lu, Ming; Yang, Zuyao; Feng, Qi et al. The characteristics and prognostic value of signet ring cell histology in gastric cancer: A retrospective cohort study of 2199 consecutive patients. Medicine, 2016, 95(27): e4052 8. Liu Dan, Lu Ming. Diagnosis and treatment of gastric neuroendocrine neoplasms. Journal of Clinical Oncology. 2015;20(6):549-554 9. Lu Ming. Heterogeneity and individualized treatment of gastrointestinal neuroendocrine carcinoma (WHO G3). Chinese Journal of Medical Frontiers (Electronic Edition). 2014;6(11):16-19 10. Lu Ming, Shen Lin. Comprehensive treatment of advanced pancreatic neuroendocrine neoplasms. Chinese Journal of Practical Surgery. 2014;34(6):19-23